TORONTO, ONTARIO--(Marketwired - July 5, 2016) - Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) today announced that scientists at a corrosion research laboratory have confirmed that Arch's 'Borg' peptides display significant anti-corrosion performance on stainless steel.
Dr. Frank Cheng and his team at the Corrosion, Pipeline Integrity and Advanced Material Technology Laboratory at the University of Calgary recently tested the Arch peptide coating technology invented by Arch scientist Dr. Randall Irvin at the University of Alberta. Researchers found that the most effective of the Arch Borg peptides reduce corrosion on 304 stainless steel by up to 85% in electrolyte solution.
Details of their findings have been accepted for publication by the journal Materials Science and Engineering C: Materials for Biological Applications. The publication titled "Peptide-based biocoatings for corrosion protection of stainless steel biomaterial in chloride solutions" by Muruve et al can be found at http://www.sciencedirect.com/science/article/pii/S0928493116306221 until it is assigned to the November 2016 issue of the journal.
Increasing corrosion resistance of stainless steel and other alloys has potential benefit in numerous applications, particularly in the medical implant and device sectors. Due to prolonged contact with physiologic fluids, metallic biomedical implants are susceptible to corrosion which can contribute to adverse effects in patients and/or device failure. Arch's development of the Borg peptide coatings for these sectors is ongoing.
About Arch Biopartners
Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; MetaMx, which targets elusive brain tumor initiating cells; Metablok, a potential treatment for sepsis and cancer metastasis; and, 'Borg' peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.
For more information on Arch Biopartners, other public documents Arch has filed on SEDAR and its technologies including, please visit www.archbiopartners.com.
The Company currently has 53,849,679 common shares outstanding.
All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.